迷走神经刺激参数实践差异与质量改进试点研究
单中心回顾性分析了2013-2022年植入VNS的耐药性癫痫患者(n=62)与2023-2024年干预后患者(n=24)的参数设置差异。干预包括术中激活VNS并在12周内滴定至1.5 mA治疗剂量,结果显示干预后启动延迟和治疗阈值达标时间显著缩短,及时达标比例显著提高。
要点
- 干预后VNS启动延迟从15天降至0天,治疗阈值达标时间从57.5周缩短至10周
- 12周内达到治疗阈值的比例从14%升至68.18%
- 标准化方案和计划性程控可显著提高及时达标率
核心结论
- VNS参数设置存在较大实践差异且治疗利用不足,试点干预后得到改善,标准化方案可确保及时给予治疗参数。
研究设计与样本
- 单中心回顾性分析,纳入2013-2022年植入VNS的耐药性癫痫患者为组1(n=62),2023-2024年植入者为干预后组2(n=24)。
主要发现
- 组1启动VNS治疗中位延迟15天(IQR 10.75),达到治疗阈值中位时间57.5周(IQR 72.93)。
- 组2启动延迟中位0天(IQR 0),达到治疗阈值中位时间10周(IQR 6),与组1比较p<0.001。
- 达到治疗阈值的患者比例从组1的80.65%升至组2的91.67%。
- 12周内达到治疗阈值的比例从组1的14%(7/50)升至组2的68.18%(15/22),p<0.001。
- 中断时间序列分析显示及时达标比例每3个月增加13.26个百分点(p=0.029)。
关键数值与推荐
- 干预措施包括术中激活VNS并在12周内滴定至治疗剂量1.5 mA。
- 逻辑回归显示干预后组和计划性程控与及时达标相关的OR分别为6.58(p=0.001)和56.77(p<0.001)。
临床怎么用
- 建议采用标准化方案,术中激活VNS并计划性程控,在12周内滴定至1.5 mA以尽早达到治疗参数。
局限性
- 单中心回顾性设计,样本量有限,干预组仅24例,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to access vagus nerve stimulation (VNS) parameters for the management of drug-resistant epilepsy (DRE) and to implement a pilot quality improvement initiative to ensure that uniform and consistent literature-supported parameters are used for optimal seizure control in patients with DRE. METHODS: A single-institution retrospective analysis was performed to assess VNS parameters of patients with DRE who underwent implantation from 2013 to 2022, before the intervention was introduced (group 1). Patients who underwent implantation from 2023 to 2024 comprised the postintervention group (group 2), with intervention that included activating VNS intraoperatively and titration to a therapeutic dose of 1.5 mA within 12 weeks. Parameters between groups were compared. Statistical control charts were used to assess process stability. An interrupted time series (ITS) analysis was conducted to assess the impact of the intervention over time, adjusting for preintervention trends. RESULTS: Eighty-six patients (50% female, mean age 25.4 [SD 15.4] years) were included. Group 1 (n = 62) had delays in initiation of VNS therapy following implantation (median 15 [IQR 10.75] days) and achieving the therapeutic threshold (median 57.5 [IQR 72.93] weeks). Group 2 (n = 24) showed no delay to initiation (median 0 [IQR 0] days) and reached the therapeutic threshold early (median 10 [IQR 6] weeks) compared with group 1 (p < 0.001). Patients for whom the therapeutic threshold was reached during the clinical course increased from 80.65% in group 1 to 91.67% in group 2. Among them, the proportion reaching that threshold within 12 weeks of implantation increased significantly from 14% (7/50) in group 1 to 68.18% (15/22) in group 2 (p < 0.001). Individual and moving range charts, assessed using Levene's test for variance, showed greater process stability and consistency in group 2. ITS analysis showed that the intervention had a sustained and significant impact; the proportion of patients with timely therapeutic parameters increased by 13.26 percentage points every 3 months (p = 0.029). Logistic regression analyses showed the postintervention group and use of scheduled programming had greater odds of achieving timely therapeutic parameters (OR 6.58 [p = 0.001] and 56.77 [p < 0.001], respectively). CONCLUSIONS: Substantial practice variability in VNS parameter settings with suboptimal utilization of therapy existed, which improved following introduction of the pilot intervention. Standardized protocols can ensure timely delivery of therapeutic parameters. These strategies have been underutilized in earlier studies, likely overestimating the time to response from VNS therapy.
引用
- Pahari S, Delaney H, Adelson PD, et al. Practice variability in vagus nerve stimulation settings for drug-resistant epilepsy and a pilot quality improvement initiative to optimize stimulation parameters. J Neurosurg. 2026. PMID: 41719537. doi:10.3171/2025.9.JNS251489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。